Alerta

MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE

Resumen de: AU2025227271A1

This application pertains to the use of Compound (A): or a pharmaceutically acceptable salt thereof, for the treatment of various diseases or disorders, including, for example, advanced non-Hodgkin lymphoma (NHL), relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL), transformed follicular lymphoma, nodal T-follicular helper cell lymphoma (nTFHL), relapsed/refractory (R/R) nodal T-follicular helper cell lymphoma, nodal T-follicular helper cell lymphoma - angioimmunoblastic type (nTFHL- Al) / advanced angioimmunoblastic T-cell lymphoma (AITL), or relapsed/refractory (R/R) nodal T-follicular helper cell lymphoma - angioimmunoblastic type (nTFHL-AI) / angioimmunoblastic T-cell lymphoma (AITL).

(+)BAYK8644 FOR USE IN METHODS OF TREATING LEUKEMIA OR LYMPHOMA

Resumen de: WO2026172270A1

A method of impairing cancer cell growth in a mammal having leukemia or lymphoma is disclosed, the method including administering to the mammal a pharmaceutical composition comprising a pharmacologically active amount of (+)-BAY K8644 as a monotherapy or in combination with the tyrosine kinase inhibitor, Ibrutinib.

ANAPLASTIC LYMPHOMA KINASE (ALK) DEGRADERS AND USES THEREOF

Resumen de: WO2026174042A1

Provided are compounds of the structural Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with ALK.

COMPOSITIONS FOR TREATMENT OF CANCER AND USES THEREOF

Resumen de: WO2026174057A1

The present disclosure provides for compositions comprising a combination of marine biomass extracts for use in the treatment of cancer, where the cancer is a leukemia, a bladder cancer, a gastric cancer, a breast cancer, a multiple myeloma, a lung cancer, or a pancreatic cancer. Further provided herein are biomass compositions having extracts from Holothuria scabra, Holothuria nobilis, Heliocidaris erythrogramma, Styela clava, and Sargassum pallidum. Moreover, in such compositions the majority components may be extracts from sea cucumber.

NANOBODIES AND NANOBODY-BASED CARS AND METHODS OF USING THE SAME TO TARGET BLOOD CANCERS

Resumen de: WO2026173613A2

The present disclosure provides nanobodies that specifically target blood cancer antigens such as TIM-3, CLEC12a, BCMA, CD38, CD229, SLAMF7, and BAFF-R, and methods of using the same to treat blood cancers such as AML and multiple myeloma. The present disclosure also provides engineered immune cells comprising nanobody-based chimeric antigen receptors (CARs) that include nanobodies that specifically target blood cancer antigens such as TIM-3, CLEC12a, BCMA, CD38, CD229, SLAMF7, and BAFF-R, and methods of using the same to treat blood cancers such as AML and multiple myeloma.

PHARMACEUTICAL COMPOSITION COMPRISING PIPERIDINE RING COMPOUND, AND USE THEREOF

Resumen de: WO2026171195A1

The present invention provides a pharmaceutical composition comprising a piperidine ring compound, and a use thereof. Specifically provided is a pharmaceutical composition, comprising a compound represented by formula (I) or a pharmaceutically acceptable salt thereof and CHOP or CHOEP. The pharmaceutical composition provided by the present invention has synergistic advantages, and has good therapeutic efficacy against lymphoma.

Compounds

Resumen de: GB2704112A

A compound of formula (I), or a pharmaceutically acceptable salt or hydrate thereof, is provided, wherein R groups are as defined herein, X-Y is -NHSO2-, A is selected from: a C4-C8-cycloalkyl group; a bicyclic C5-C12-cycloalkyl group; and a C4-C8-cycloalkyl group fused to an aryl or heteroaryl group; each of which is optionally substituted by one or more R4 groups; R1 is haloalkyl or OR3; R2 is H or halo; R3 is alkyl or benzyl; and each R4 is independently alkyl or halo. B is NR6R7, wherein R6 and R7 are linked to form a polycyclic group containing at least one spiro carbon, and which polycyclic group optionally contains one or more groups independently selected from NR35, CO, O, S, SO and SO2, and is optionally further substituted by one or more R5 groups; each R5 is independently selected from COOH, CONR8R9, CONHSO2R10, NR30R31, CO2-alkyl, OH, alkyl, halo, haloalkyl, alkoxy, aminoalkyl, and hydroxyalkyl. The compounds modulate ERAP2 and are useful in treating proliferative, viral, immune or inflammatory disorders, particularly cancer or leukaemia. The compounds stimulate a neo-antigen directed immune response. Methods of producing antigen-presenting cells and immunogenic compositions are also disclosed. Exemplified compounds include N-(2-(cyclohexylamino)-5-(trifluoromethyl)phenyl)-2,4-dioxo-1,3,7-triazaspiro4,5decane-7-sulfonamide No Figure

METHODS FOR TREATING MULTIPLE MYELOMA COMPRISING AN ANTI-CD38 ANTIBODY COMBINED WITH BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE

Resumen de: WO2025080911A1

The present disclosure is directed to methods of treating multiple myeloma. The present disclosure is directed to methods of treating newly diagnosed multiple myeloma in a subject in need thereof, for example, by subcutaneously administering to the subject a pharmaceutical composition comprising an anti-CD38 antibody in combination with bortezomib, lenalidomide, and dexamethasone.

METHODS FOR PREDICTING RESPONSIVENESS OF LYMPHOMA TO DRUG AND METHODS FOR TREATING LYMPHOMA

Nº publicación: EP4791907A1 19/08/2026

Solicitante:

BRISTOL MYERS SQUIBB CO [US]
Bristol-Myers Squibb Company

Resumen de: WO2025080543A1

Provided herein are methods of predicting the responsiveness of a lymphoma patient to a cancer treatment. Also provided herein are methods of treating a lymphoma patient based on predicting the responsiveness of the lymphoma patient to a cancer treatment.